肾透明细胞癌患者血清可溶性白细胞介素-2受体水平的变化及意义  

Changes and significance of serum soluble interleukin 2 receptor in patients with renal clear cell carcinoma

作　　者：晋学飞[1] 王尧[1] 闫世贤[2] 王凯臣[1] 

机构地区：[1]吉林大学中日联谊医院泌尿外科,长春130033 [2]吉林大学第一医院胃结直肠外科,长春130021

出　　处：《中华实验外科杂志》2016年第1期242-244,共3页Chinese Journal of Experimental Surgery

摘　　要：目的探讨可溶性白细胞介素-2受体（sIL-2R）在肾透明细胞癌（RCC）患者血清中的水平变化及临床意义。方法选取84例RCC患者为观察组，84例健康成年人为对照组，采用酶联免疫吸附试验（ELISA）检测所有受试者血清中sIL-2R的水平，分析其与临床资料的关系，并对观察组患者进行随访。结果观察组血清sIL-2R水平[（948．5±51．6）ng／L]显著高于对照组[（433．1±76．9）ng／L]（P〈0．05）；术前血清sIL-2R水平与是否吸烟、临床分期和是否发生远处转移有关（P〈0．05）；根据ROC曲线计算，sIL-2R=988．8ng／L为截点；高sIL-2R组（H组）平均血清sIL-2R水平[（1088．4±96．7）ng／L]显著高于低sIL-2R组（L组）[（731．6±103．4）ng／L]（P〈0．05）；H组患者的总体生存率（35．59％，21／59）显著低于L组（66．67％，12／18，P〈0．05）；临床分期、是否发生远处转移和血清sIL-2R水平是影响RCC预后的独立危险因素（P〈0．05）。结论RCC患者血清中sIL-2R水平显著升高，血清高sIL-2R水平可能预示预后较差。Objective To investigate the changes of soluble interleukin -2 receptor （sIL -2R） in serum of patients with renal clear cell carcinoma （RCCC） and its clinical significance. Methods Eigthy - four cases of RCCC were selected as the observation group and 84 healthy adults as control group. The serum level of sIL -2R was detected by enzyme -linked immunosorbent assay （ELISA）. The relationship between sIL - 2R and clinical data was analyzed. Results The serum level of sIL - 2R in observation group [ （948.5 ±51.6） ng/L] was significantly higher than in the control group [ （433.1 ±76. 9） ng/L, P 〈0. 05]. Preoperative serum sIL- 2R levels were associated with smoking, clinical stage and distant metastasis （ P 〈 0. 05 ）. The cut- off value of sIL - 2R was 988. 8 ng/L based on the ROC curve. The serum level of sIL - 2R in H group [ （ 1 088.4 ± 96.7 ） ng/L ] was significantly higher than in L group [ （731.6 ± 103.4） ng/L,P 〈0. 05], and the overall survival rate （35.59%, 21/59） in H group was lower than in L group significantly （66. 67%, 12/18） （P 〈0. 05）. Conclusion Serum sIL-2R levels were significantly elevated in patients with RCCC, and the serum level of sIL -2R may indicate a poor prognosis.

关 键 词：肾透明细胞癌 可溶性白细胞介素-2 酶联免疫吸附试验 早期诊断 

分 类 号：R735.2[医药卫生—肿瘤]